Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
Olema Pharmaceuticals (OLMA) Stock Price & Analysis
189 Followers
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.19 - $7.45
Previous Close$5.37
Volume142.55K
Average Volume (3M)181.85K
Market Cap
$214.00M
Enterprise Value$35.23M
Total Cash (Recent Filing)$185.95M
Total Debt (Recent Filing)$2.29M
Price to Earnings (P/E)-2.0
Beta2.13
Next Earnings
Aug 08, 2023EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding40,761,714
10 Day Avg. Volume191,563
30 Day Avg. Volume181,853
Standard Deviation0.31
R-Squared0.15
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$16.20Price Target Upside213.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Olema Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.19 and its highest was $7.45 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Aug 08, 2023 which is in 68 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on May 09, 2023. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.037.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -$0.73.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 40,761,715 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went down -8.666%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Olema Pharmaceuticals’s shares valued at N/A.
---
Olema Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.20 (213.35% Upside)
$16.20 (213.35% Upside)
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.03%
12-Months-Change
Fundamentals
Return on Equity
-50.01%
Trailing 12-Months
Asset Growth
-29.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
Top 5 ETFs holding OLMA
iShares Core S&P Total U.S. Stock Market ETF
$189.00
Up to five ETFs with an Outperform Smart Score that hold OLMA. The ETFs are listed according to market value of OLMA within the ETF
---
---